GO:0004615 phosphomannomutase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004615 phosphomannomutase activity catalyzes the interconversion of alpha-D-mannose 1-phosphate and D-mannose 6-phosphate, a critical step in GDP-mannose synthesis and protein N-glycosylation.
• Biallelic mutations in PMM2, encoding phosphomannomutase 2, cause PMM2-CDG, the most common congenital disorder of glycosylation, with multisystem clinical features [1,3].
• PMM2-CDG diagnosis relies on clinical suspicion, transferrin isoelectric focusing, and confirmatory PMM2 genetic testing; phosphomannomutase enzyme activity in leukocytes can support diagnosis [1,2].
• PMM2 deficiency leads to neural and metabolic dysregulation, including altered N-glycosylation of neural cell adhesion molecules and endocrine axes [5,6].
• O-GlcNAcylation modulates the expression and abundance of N-glycosylation machinery, revealing crosstalk between glycosylation pathways in inherited glycosylation disorders.
• Genotype-phenotype correlations in PMM2-CDG are complex; some missense variants retain residual activity, and 137-patient cohorts show variable severity.
Description
Phosphomannomutase activity (GO:0004615) is a molecular function defined as the catalysis of the reaction alpha-D-mannose 1-phosphate = D-mannose 6-phosphate. This enzymatic step is essential for the synthesis of GDP-mannose, the primary donor of mannose residues for N-linked glycosylation, glycosylphosphatidylinositol anchors, and other mannosylated glycoconjugates. In humans, the principal enzyme carrying this activity is phosphomannomutase 2 (PMM2), and its deficiency causes PMM2-congenital disorder of glycosylation (PMM2-CDG), the most prevalent inherited glycosylation defect [1,3]. Researchers study phosphomannomutase activity to understand glycosylation pathway flux, to diagnose and manage PMM2-CDG, and to explore therapeutic strategies including mannose supplementation and pharmacological chaperones [1,5]. The enzyme is also relevant to broader questions in neurodevelopment, immune function, and endocrine regulation because N-glycosylation affects a vast array of secreted and membrane proteins [5,6].
phosphomannomutase activity At A Glance
| GO ID | GO:0004615 |
|---|---|
| GO term | phosphomannomutase activity |
| Ontology | molecular_function |
| Synonym | alpha-D-mannose 1,6-phosphomutase activity; D-mannose 1,6-phosphomutase activity; mannose phosphomutase activity; phosphomannose mutase activity |
| Definition | Catalysis of the reaction: alpha-D-mannose 1-phosphate = D-mannose 6-phosphate. |
| Major function | Interconversion of mannose 1-phosphate and mannose 6-phosphate, essential for GDP-mannose synthesis and protein glycosylation. |
| Human gene | PMM2 (phosphomannomutase 2) |
| Associated disease | PMM2-CDG (congenital disorder of glycosylation type Ia) |
| Subcellular location | Cytoplasm |
What Is GO:0004615?
Phosphomannomutase activity (GO:0004615) is the catalytic function that interconverts alpha-D-mannose 1-phosphate and D-mannose 6-phosphate. This reversible mutase reaction involves the intramolecular transfer of a phosphate group between the 1 and 6 positions of mannose. The activity is required for the biosynthesis of GDP-mannose, which serves as the mannose donor for N-glycosylation and other glycosylation reactions. In humans, the enzyme phosphomannomutase 2 (PMM2) is the major protein exhibiting this activity, and its deficiency leads to a congenital disorder of glycosylation [1,3].
Why Is phosphomannomutase activity Important in Cell Biology?
Phosphomannomutase activity is a critical node in the glycosylation pathway because it supplies mannose 6-phosphate for GDP-mannose production, which is required for N-glycosylation, O-mannosylation, and glycosylphosphatidylinositol anchor biosynthesis. Defects in this activity cause PMM2-CDG, a multisystem disorder with neurological, hepatic, cardiac, and endocrine manifestations [1,3]. Understanding phosphomannomutase function helps researchers dissect glycosylation-related disease mechanisms, develop diagnostic assays, and evaluate therapeutic approaches such as mannose supplementation or chaperones [1,5,6].
• PMM2-CDG is the most common congenital disorder of glycosylation, affecting multiple organ systems [1,3].
• Phosphomannomutase activity is required for GDP-mannose synthesis, which is essential for N-glycosylation of proteins.
• Reduced phosphomannomutase activity leads to hypoglycosylation of serum glycoproteins, a hallmark of PMM2-CDG [1,4].
• PMM2 deficiency causes neural and metabolic dysregulation, including altered neural cell adhesion and endocrine dysfunction [5,6].
• O-GlcNAcylation modulates N-glycosylation machinery, indicating crosstalk between glycosylation pathways.
• Genotype-phenotype studies in PMM2-CDG reveal variable severity and incomplete penetrance, complicating prognosis.
• Enzyme activity assays in leukocytes can support diagnosis when genetic testing is inconclusive.
• Therapies targeting glycosylation defects, such as mannose supplementation, are under investigation.
• Phosphomannomutase activity is conserved across eukaryotes, making model organisms useful for study.
• Research on PMM2-CDG provides insights into broader glycosylation disorders and personalized medicine.
Molecular Mechanism of phosphomannomutase activity
Substrate binding and catalysis
In simple terms: The enzyme grabs mannose 1-phosphate and moves the phosphate to a different spot on the sugar.
Phosphomannomutase catalyzes the reversible transfer of a phosphate group between the C1 and C6 positions of mannose. The reaction proceeds via a phosphoenzyme intermediate, where the enzyme itself becomes transiently phosphorylated. This mechanism requires a divalent metal ion, typically magnesium, and involves conserved active-site residues. The interconversion of alpha-D-mannose 1-phosphate and D-mannose 6-phosphate is essential for maintaining cellular pools of mannose 6-phosphate, which feeds into GDP-mannose synthesis.
Role in GDP-mannose synthesis
In simple terms: The product of this enzyme is turned into a sugar carrier that delivers mannose to proteins.
D-mannose 6-phosphate produced by phosphomannomutase is converted by phosphomannose isomerase to fructose 6-phosphate or by phosphomannomutase back to mannose 1-phosphate. Mannose 1-phosphate then reacts with GTP to form GDP-mannose, the donor substrate for mannosyltransferases in the endoplasmic reticulum and Golgi. Thus, phosphomannomutase activity directly influences the availability of GDP-mannose for N-glycosylation, O-mannosylation, and GPI anchor biosynthesis [1,4].
Enzyme structure and isoforms
In simple terms: Different versions of the enzyme exist, but PMM2 is the main one in humans.
In humans, two phosphomannomutase genes exist: PMM1 and PMM2. PMM2 is the predominant isoform and its deficiency causes PMM2-CDG. PMM1 can also catalyze the reaction but is less critical for glycosylation. The PMM2 protein forms a homodimer and contains a conserved core domain with a catalytic aspartate residue that participates in the phosphoenzyme intermediate. Structural studies have revealed that disease-causing mutations often affect dimerization or active-site architecture [1,3].
Regulation of phosphomannomutase activity
In simple terms: The enzyme's activity can be tuned by cellular conditions and interacting proteins.
Phosphomannomutase activity is regulated at multiple levels. Transcriptional regulation of PMM2 responds to cellular stress and glycosylation demand. Post-translational modifications, such as O-GlcNAcylation, can modulate the expression and abundance of N-glycosylation machinery, including PMM2. Additionally, feedback inhibition by downstream metabolites and availability of substrates influence flux through the pathway. In PMM2-CDG, residual activity of mutant enzymes correlates with clinical severity, suggesting that even small changes in activity can have significant physiological effects.
Key Genes Involved in GO:0004615 phosphomannomutase activity
The following genes and proteins are directly or indirectly involved in phosphomannomutase activity and its associated pathways.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PMM2 | Encodes phosphomannomutase 2, the principal enzyme with GO:0004615 activity | Mutations cause PMM2-CDG; target for diagnosis and therapy [1,3] |
| PMM1 | Encodes phosphomannomutase 1, a minor isoform with similar activity | May compensate for PMM2 deficiency; less studied |
| MPI | Phosphomannose isomerase, converts mannose 6-phosphate to fructose 6-phosphate | Deficiency causes MPI-CDG; interacts with PMM2 pathway |
| GMPPA | GDP-mannose pyrophosphorylase A, synthesizes GDP-mannose | Defects cause GMPPA-CDG; related glycosylation disorder |
| GMPPB | GDP-mannose pyrophosphorylase B, synthesizes GDP-mannose | Mutations cause muscle-eye-brain disease and CDG |
| ALG1 | Mannosyltransferase in N-glycan assembly | Defects cause ALG1-CDG; downstream of PMM2 |
| ALG2 | Mannosyltransferase in N-glycan assembly | Defects cause ALG2-CDG; related to PMM2-CDG |
| ALG3 | Mannosyltransferase in N-glycan assembly | Defects cause ALG3-CDG; glycosylation disorder |
| ALG6 | Glucosyltransferase in N-glycan assembly | Defects cause ALG6-CDG; common CDG |
| ALG8 | Glucosyltransferase in N-glycan assembly | Defects cause ALG8-CDG; glycosylation disorder |
| ALG9 | Mannosyltransferase in N-glycan assembly | Defects cause ALG9-CDG; glycosylation disorder |
| DDOST | Oligosaccharyltransferase subunit | Defects cause DDOST-CDG; N-glycosylation disorder |
| MAGT1 | Oligosaccharyltransferase subunit | Defects cause immunodeficiency and glycosylation defects |
| TUSC3 | Oligosaccharyltransferase subunit | Defects cause intellectual disability and glycosylation defects |
| SLC35A2 | UDP-galactose transporter | Defects cause SLC35A2-CDG; glycosylation disorder |
| SLC35C1 | GDP-fucose transporter | Defects cause leukocyte adhesion deficiency type II |
| GFPT1 | Glutamine-fructose-6-phosphate transaminase 1 | Defects cause congenital myasthenic syndrome with glycosylation defects |
| PMM2 (mutant) | Disease-causing variants with reduced activity | Genotype-phenotype studies and therapeutic development |
How Is phosphomannomutase activity Regulated?
Phosphomannomutase activity is regulated at transcriptional, post-translational, and metabolic levels. PMM2 expression can be induced by cellular stress and increased glycosylation demand. O-GlcNAcylation, a nutrient-sensitive modification, modulates the expression and abundance of N-glycosylation machinery, including PMM2, thereby influencing pathway flux. Additionally, the enzyme's activity is affected by substrate availability and feedback inhibition by downstream products. In PMM2-CDG, residual activity of mutant enzymes correlates with clinical severity, and some mutations respond to mannose supplementation, indicating that the pathway can be partially rescued by substrate provision [1,8].
phosphomannomutase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PMM2 | PMM2-CDG (CDG-Ia) | Patient-derived fibroblasts, PMM2 knockout cell lines, knock-in of patient mutations [1,3] |
| PMM2 | Neural dysregulation | Human induced pluripotent stem cell-derived neurons with PMM2 mutations |
| PMM2 | Endocrine dysfunction | Mouse models with Pmmp2 deficiency or patient-derived cells |
| PMM2 | O-GlcNAcylation crosstalk | Cell lines with modulated O-GlcNAc transferase (OGT) or O-GlcNAcase (OGA) |
| PMM2 | Genotype-phenotype correlations | Isogenic cell lines expressing different PMM2 missense variants |
PMM2-CDG (congenital disorder of glycosylation type Ia)
PMM2-CDG is an autosomal recessive multisystem disorder caused by biallelic mutations in PMM2, leading to reduced phosphomannomutase activity [1,3]. Clinical features include developmental delay, hypotonia, cerebellar hypoplasia, seizures, failure to thrive, and endocrine abnormalities [1,6]. Diagnosis is based on clinical suspicion, transferrin isoelectric focusing showing a type I pattern, and confirmatory genetic testing. Enzyme activity assays in leukocytes can support diagnosis. Management is supportive, with multidisciplinary care; mannose supplementation has shown limited benefit in some patients.
Neural and metabolic dysregulation in PMM2 deficiency
PMM2-deficient human in vitro neural models show altered N-glycosylation of neural cell adhesion molecules, leading to impaired neuronal migration and network formation. Metabolic dysregulation includes changes in lipid and energy metabolism, which may contribute to neurological symptoms. These findings highlight the importance of phosphomannomutase activity for normal brain development and function.
Endocrine manifestations of PMM2-CDG
PMM2-CDG patients frequently present with endocrine abnormalities, including hypogonadism, delayed puberty, and growth hormone deficiency. A recent study explored the role of N-glycosylation on endocrine axes, showing that defective glycosylation of hormones and receptors may underlie these features. This underscores the need for endocrine monitoring in PMM2-CDG patients.
O-GlcNAcylation crosstalk in glycosylation disorders
O-GlcNAcylation modulates the expression and abundance of N-glycosylation machinery, including PMM2, in an inherited glycosylation disorder. This crosstalk suggests that targeting O-GlcNAc cycling could influence the severity of PMM2-CDG and other glycosylation defects, offering potential therapeutic avenues.
From phosphomannomutase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of complete loss of phosphomannomutase activity? | PMM2 knockout cell lines (e.g., HEK293, HeLa) via CRISPR-Cas9 |
| How do specific patient mutations affect enzyme function? | Point-mutation knock-in cell lines expressing PMM2 variants (e.g., R141H, F119L) |
| Can wild-type PMM2 rescue the glycosylation defect? | Knock-in of wild-type PMM2 into patient-derived cells or overexpression |
| How does PMM2 deficiency affect neural development? | Human iPSC-derived neurons with PMM2 mutations |
| What is the role of O-GlcNAcylation in PMM2-CDG? | Cell lines with OGT/OGA knockout or overexpression |
| Can mannose supplementation improve glycosylation? | Patient fibroblasts treated with mannose, monitored by transferrin IEF |
How to Study the phosphomannomutase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Enzyme activity assay | Phosphomannomutase catalytic activity | Diagnosis of PMM2-CDG, assessing mutant enzyme function |
| Transferrin IEF | Sialylation of transferrin | Screening for congenital disorders of glycosylation |
| Mass spectrometry | Glycan structures and site occupancy | Detailed glycosylation profiling in PMM2-CDG |
| Sanger sequencing | PMM2 gene variants | Confirmatory genetic testing |
| Western blot | Protein expression and O-GlcNAcylation levels | Studying crosstalk between glycosylation pathways |
| Immunofluorescence | Subcellular localization of PMM2 | Investigating enzyme trafficking and localization |
| CRISPR-Cas9 knockout | Loss of PMM2 function | Creating isogenic models for functional studies |
| RNA-seq | Transcriptional changes in glycosylation genes | Identifying compensatory pathways in PMM2 deficiency |
Enzyme activity assays
Phosphomannomutase activity can be measured in cell lysates or leukocytes using coupled enzymatic assays that monitor the conversion of mannose 1-phosphate to mannose 6-phosphate. These assays are used for diagnosis of PMM2-CDG and for assessing residual activity of mutant enzymes.
Glycosylation analysis
Transferrin isoelectric focusing (IEF) and mass spectrometry of serum transferrin are standard methods to detect hypoglycosylation in PMM2-CDG. These techniques reveal the characteristic type I pattern of CDG and are used for diagnosis and monitoring.
Genetic testing
Sanger sequencing or next-generation sequencing of PMM2 is used to identify disease-causing variants. Genotype-phenotype studies require comprehensive mutation analysis and correlation with clinical data.
Omics approaches
Transcriptomics, proteomics, and glycomics can reveal global changes in glycosylation pathways and identify biomarkers. O-GlcNAcylation can be assessed by Western blot with O-GlcNAc-specific antibodies or by mass spectrometry.
How CRISPR Can Be Used to Study GO:0004615 phosphomannomutase activity
Knockout
CRISPR-Cas9 knockout of PMM2 in cell lines (e.g., HEK293, HeLa) creates models of complete phosphomannomutase deficiency. These models are used to study the consequences of loss of activity on glycosylation, cell viability, and stress responses. Knockout cells can be complemented with wild-type or mutant PMM2 to assess rescue.
Point Mutation
Knock-in of specific patient mutations (e.g., R141H, F119L) into the endogenous PMM2 locus allows study of genotype-phenotype relationships. These models help determine residual enzyme activity and response to therapeutic interventions such as mannose or pharmacological chaperones.
Knock-in
Tagged knock-in of PMM2 (e.g., with GFP or HA) enables visualization and immunoprecipitation of the enzyme. This approach is useful for studying protein interactions, subcellular localization, and dynamics of phosphomannomutase in live cells.
Overexpression
Overexpression of wild-type or mutant PMM2 in cell lines can rescue glycosylation defects or induce dominant-negative effects. Overexpression models are used to test the impact of increased phosphomannomutase activity on glycosylation flux and to evaluate potential therapies.
How EDITGENE Supports phosphomannomutase activity Research
Researchers studying phosphomannomutase activity-related genes often need to determine whether a candidate gene is causally involved in glycosylation disorders, whether specific mutations alter enzyme function, or whether modulating activity can rescue cellular phenotypes. EDITGENE provides comprehensive CRISPR-based services to create precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for phosphomannomutase activity research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PMM1 Knockout HEK293 Cell Line | EDJ-KQ5493 | Human | 5372 | Details Get a Quote |
| PMM2 Knockout HEK293 Cell Line | EDJ-KQ5494 | Human | 5373 | Details Get a Quote |
| PMM2 Knockout HCT 116 Cell Line | EDJ-KQ27478 | Human | 5373 | Details Get a Quote |
| PMM1 Knockout A-549 Cell Line | EDJ-KQ28722 | Human | 5372 | Details Get a Quote |
| PMM1 Knockout HCT 116 Cell Line | EDJ-KQ28723 | Human | 5372 | Details Get a Quote |
| PMM1 Knockout HeLa Cell Line | EDJ-KQ28724 | Human | 5372 | Details Get a Quote |
| PMM2 Knockout A-549 Cell Line | EDJ-KQ28725 | Human | 5373 | Details Get a Quote |
| PMM2 Knockout HeLa Cell Line | EDJ-KQ28727 | Human | 5373 | Details Get a Quote |
Displaying Records 1 To 8 Of 8 Records
Frequently Asked Questions About phosphomannomutase activity
What is phosphomannomutase activity?
Phosphomannomutase activity (GO:0004615) is the catalytic function that interconverts alpha-D-mannose 1-phosphate and D-mannose 6-phosphate, a key step in GDP-mannose synthesis for protein glycosylation.
What genes are involved in phosphomannomutase activity?
The primary human gene is PMM2, encoding phosphomannomutase 2. PMM1 encodes a related isoform. Other genes in the pathway include MPI, GMPPA, and GMPPB.
What diseases are associated with phosphomannomutase activity?
Deficiency causes PMM2-CDG (congenital disorder of glycosylation type Ia), a multisystem disorder with neurological, hepatic, and endocrine features [1,3].
How is phosphomannomutase activity measured?
Enzyme activity can be measured in leukocytes or cell lysates using coupled enzymatic assays. Diagnosis of PMM2-CDG also uses transferrin isoelectric focusing and genetic testing [1,2].
What are the symptoms of PMM2-CDG?
Symptoms include developmental delay, hypotonia, cerebellar hypoplasia, seizures, failure to thrive, and endocrine abnormalities [1,6].
Can phosphomannomutase activity be restored?
Mannose supplementation and pharmacological chaperones are under investigation. Residual activity of mutant enzymes correlates with clinical severity [1,8].
What is the role of PMM2 in glycosylation?
PMM2 converts mannose 1-phosphate to mannose 6-phosphate, which is used to synthesize GDP-mannose, the donor for N-glycosylation.
How does O-GlcNAcylation affect phosphomannomutase activity?
O-GlcNAcylation modulates the expression and abundance of N-glycosylation machinery, including PMM2, revealing crosstalk between glycosylation pathways.
What model systems are used to study phosphomannomutase activity?
Common models include patient fibroblasts, CRISPR knockout cell lines, iPSC-derived neurons, and mouse models [1,5].
What is the prognosis for PMM2-CDG?
Prognosis varies widely; some patients have severe early-onset disease, while others have milder courses. Genotype-phenotype correlations are complex.
Conclusion
Phosphomannomutase activity (GO:0004615) is a fundamental enzymatic function required for GDP-mannose synthesis and protein glycosylation. Its deficiency causes PMM2-CDG, a multisystem disorder with significant morbidity. Research into the molecular mechanisms, genotype-phenotype relationships, and therapeutic strategies for PMM2-CDG continues to advance, supported by CRISPR-based models and omics technologies. Understanding this activity provides insights into glycosylation biology and potential treatments for congenital disorders of glycosylation.
References
- 1. Altassan R et al.. 2019. International clinical guidelines for the management of phosphomannomutase 2-congenital disorders of glycosylation: Diagnosis, treatment and follow up.. J Inherit Metab Dis 42(1):5-28 PMID: 30740725
- 2. Dave MB et al.. 2022. Leukocyte Phosphomannomutase and Phosphomannose Isomerase Activity in an Indian Cohort.. Indian J Clin Biochem 37(2):238-241 PMID: 35463115
- 3. Adam MP et al.. 1993. PMM2-CDG.. PMID: 20301289
- 4. Freeze HH et al.. 1999. Molecular basis of carbohydrate-deficient glycoprotein syndromes type I with normal phosphomannomutase activity.. Biochim Biophys Acta 1455(2-3):167-78 PMID: 10571010
- 5. Radenkovic S et al.. 2024. Neural and metabolic dysregulation in PMM2-deficient human in vitro neural models.. Cell Rep 43(3):113883 PMID: 38430517
- 6. Del Medico G et al.. 2025. Phosphomannomutase 2-congenital disorder of glycosylation: exploring the role of N-glycosylation on the endocrine axes.. Front Endocrinol (Lausanne) 16:1594118 PMID: 40771275
- 7. Matheny-Rabun C et al.. 2024. O-GlcNAcylation modulates expression and abundance of N-glycosylation machinery in an inherited glycosylation disorder.. Cell Rep 43(11):114976 PMID: 39561044
- 8. Pajusalu S et al.. 2024. Genotype/Phenotype Relationship: Lessons From 137 Patients With PMM2-CDG.. Hum Mutat 2024:8813121 PMID: 40225925
